Wave Life Sciences
Wave develops RNA-targeting medicines using RNA interference and RNA editing approaches. Its October 27, 2026 update describes WVE-007 as an investigational GalNAc-siRNA and WVE-006 as an investigational RNA-editing oligonucleotide. These are distinct modalities, not mRNA products.
Corporate information
- Company entity
- Wave Life Sciences
- Headquarters / principal office
- Cambridge, Massachusetts, United States ↗
- Founded
- 2012 ↗
- Ownership / capital status
- Publicly tradedNasdaq-listed: WVE ↗
- Official corporate reference
- https://wavelifesciences.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Wave develops RNA-targeting medicines using RNA interference and RNA editing approaches. Its October 27, 2026 update describes WVE-007 as an investigational GalNAc-siRNA and WVE-006 as an investigational RNA-editing oligonucleotide. These are distinct modalities, not mRNA products.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Wave Q3 2026 results and business update
- Official corporate website audit
- Primary corporate profile / legal-entity disclosure